SIS has various applications within a few areas of research:

Anti-Inflammatory Disease – This is the leading scientific focus of the company. The company is conducting a Phase II clinical trial for Atopic Dermatitis in Israel.
Anti-Viral Infective Disease – an advanced clinical trial (Phase II) for Herpes Labialis (HSV1) was completed successfully. The company is planning a Phase III clinical trial in the US. Additional Herpes indications (Genital, Ocular, Zoster) are in various stages of research.

Pain relief – both peptides (ZEP-3 and ZEP-4) exhibited significant analgesic activity in various indications such as Osteoarthritis (OA), Herpes Labialis, and Ocular pain.

SIS completed a Phase I clinical study on healthy volunteers. This Phase I is suitable for planned clinical studies in several indications such as Herpes Labialis, Herpes Zoster, Atopic Dermatitis, and Burns.
Herpes Labialis -The company has completed a Phase II clinical study in Herpes Labialis and preparing the Pre-IND meeting for Phase III clinical study in the US.
Atopic Dermatitis – SIS is conducting a Phase II clinical study for Atopic Dermatitis in Israel in 9 sites at the leading dermatology departments at hospitals and community clinics.
Acyclovir-resistant -In addition, Efficacy studies have shown that ZEP-3 is equally effective both on HSV-1 and HSV-2 for acyclovir-resistant viruses where a growing population does not respond to the existing therapy to acyclovir resistance.
The company has completed the Pre-clinical process for ZEP-4, which is intended for the treatment of Psoriasis. Clinical trials are planned for 2022.   
The company tested the lead compound on cases of Lung Inflammation. The results show that  ZEP-3 led to a significant reduction in cytokines. Therefore, ZEP-3 is a suitable candidate for the treatment of the cytokine storm caused by COVID-19. 
Burns – SIS completed all required preclinical studies for a planned clinical study focused on Burns and is attending to submit a request for such a study.
Furthermore, the company has worked on other indications that are intended for pre-clinical research and clinical trials, such as Genital Herpes (HSV-2) and Ocular Herpes.